Gilead Sciences, Inc.

+0.69 (+1.02%)
4:19:35 PM EDT: $68.47 -0.03 (-0.04%)

Merck Announces Clinical Holds On Studies Evaluating Islatravir

Published: 12/13/2021 22:20 GMT
Gilead Sciences, Inc. (GILD) - Merck Announces Clinical Holds on Studies Evaluating Islatravir for the Treatment and Prevention of Hiv-1 Infection.
Merck-clinical Hold Based on Observations of Decreases in Total Lymphocyte & Cd4+ T-cell Counts in Some Participants Getting Islatravir in Clinical Studies.
Merck & Co Inc - With FDA's Clinical Hold, No New Studies May Be Initiated.
Merck & Co Inc - Participants Who Are Currently Receiving Islatravir As Part of Studies for Prep, Will No Longer Receive Study Drug.
Merck & Co Inc - No New Participants Will Be Screened Or Randomized in Dor/isl Studies for Treatment During Partial Clinical Hold.
Merck & Co Inc - Continues to Investigate Potential of Islatravir and Nucleoside Reverse Transcriptase Translocation Inhibitors.
Merck - Gilead, Co Made Decision to Stop All Dosing of Participants in Phase 2 Study Evaluating Combination Regimen of Islatravir & Lenacapavir.